<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Newco news</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Newco news: Oorja energizes with $30M for IPF</title>
      <description>
        <![CDATA[Oorja Bio Inc., named after the phonetic spelling of “energy” in Sanskrit, secured $30 million from founding investor Westlake Biopartners in a series A financing round to advance its in-licensing approach to develop drugs for idiopathic pulmonary fibrosis (IPF) and other fibrotic and cardiopulmonary diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731387</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731387-newco-news-oorja-energizes-with-30m-for-ipf</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-and-lungs.webp?t=1596747896" type="image/png" medium="image" fileSize="429739">
        <media:title type="plain">Heart and lungs</media:title>
      </media:content>
    </item>
    <item>
      <title>Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific</title>
      <description>
        <![CDATA[Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731224</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731224-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-currency-symbols-and-globe.webp?t=1778527058" type="image/jpeg" medium="image" fileSize="144034">
        <media:title type="plain">Eye, currency symbols and globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific</title>
      <description>
        <![CDATA[Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731193</guid>
      <pubDate>Tue, 12 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731193-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-currency-symbols-and-globe.webp?t=1778527058" type="image/jpeg" medium="image" fileSize="144034">
        <media:title type="plain">Eye, currency symbols and globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Curacle, Memento ink $1B deal for ocular TIE2/VEGF bispecific</title>
      <description>
        <![CDATA[Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731030</guid>
      <pubDate>Mon, 11 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731030-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Eye-currency-symbols-and-globe.webp?t=1778527058" type="image/jpeg" medium="image" fileSize="144034">
        <media:title type="plain">Eye, currency symbols and globe</media:title>
      </media:content>
    </item>
    <item>
      <title>Eyes are first prize for newco Link Biologics</title>
      <description>
        <![CDATA[The classic origin story for a biotech startup is that of a scientist who nurtures his work out of a university and to commercial success. For Link Biologics Ltd. and its TSG6-based pipeline, the story is the other way around; it began with now-CEO Reuben Dawkins meeting University of Manchester scientists Tony Day and Caroline Milner while he was on the lookout for “great science that needs help to make it to patients.” The three are now co-founders of Link, which spun out of the University of Manchester in 2021 and has four programs in three indications, all based on TSG-6 biology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730902</guid>
      <pubDate>Wed, 06 May 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730902-eyes-are-first-prize-for-newco-link-biologics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/Ocular-digital-eye.webp?t=1589292031" type="image/png" medium="image" fileSize="615294">
        <media:title type="plain">Rays of light beaming from eye</media:title>
      </media:content>
    </item>
    <item>
      <title>Sonire starts US study of cancer HIFU after $18M series A </title>
      <description>
        <![CDATA[Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed to ablate pancreatic tumors, after closing an $18 million series A financing round April 15.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730922</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730922-sonire-starts-us-study-of-cancer-hifu-after-18m-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas1.webp?t=1712602217" type="image/jpeg" medium="image" fileSize="143528">
        <media:title type="plain">Pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Sonire starts US study of cancer HIFU after $18M series A </title>
      <description>
        <![CDATA[Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed to ablate pancreatic tumors, after closing an $18 million series A financing round April 15.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730769</guid>
      <pubDate>Fri, 01 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730769-sonire-starts-us-study-of-cancer-hifu-after-18m-series-a</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Endocrine/Pancreas1.webp?t=1712602217" type="image/jpeg" medium="image" fileSize="143528">
        <media:title type="plain">Pancreas</media:title>
      </media:content>
    </item>
    <item>
      <title>Pilatus PLT-012 takes immunometabolic approach to reprogram TME </title>
      <description>
        <![CDATA[Pilatus Bio Inc. is working to address a major under-addressed target of current checkpoint inhibitors: metabolic stress within solid tumors. “Traditional immunotherapies release immune ‘brakes,’ but they do not address the underlying metabolic stress in tumors,” Pilatus CEO and cofounder Raven Lin said. “That’s why more than 60% of solid tumor patients do not respond to treatment.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/730671</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730671-pilatus-plt-012-takes-immunometabolic-approach-to-reprogram-tme</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Monoclonal-antibody-cancer-tumor-illustration.webp?t=1765295036" type="image/jpeg" medium="image" fileSize="555950">
        <media:title type="plain">Illustration of monoclonal antibody treatment for cancer</media:title>
      </media:content>
    </item>
    <item>
      <title>Anaptysbio’s spinout First Tracks hits the slopes</title>
      <description>
        <![CDATA[Anaptysbio Inc. announced in September of 2025 that it planned to separate its drug development business from the royalties it receives on Jemperli (dostarlimab) from GSK plc and imsidolimab from Vanda Pharmaceuticals Inc. Just seven months later, on April 20, 2026, well ahead of its “year-end 2026” goal, First Tracks Biotherapeutics Inc., the drug development arm of the company, started trading as a standalone company on Nasdaq under the ticker symbol TRAX.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730618</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730618-anaptysbios-spinout-first-tracks-hits-the-slopes</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Science-research-structures-microscope.webp?t=1682529172" type="image/png" medium="image" fileSize="579163">
        <media:title type="plain">Drug R&amp;D concept image.</media:title>
      </media:content>
    </item>
    <item>
      <title>Remedy pushes ‘cell-free’ secretome therapy for IPF into phase I </title>
      <description>
        <![CDATA[“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told <em>BioWorld</em>. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730576</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730576-remedy-pushes-cell-free-secretome-therapy-for-ipf-into-phase-i</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ayele-Dilion-Mashiah-CEO-Remedy-4-15.webp?t=1776282566" type="image/jpeg" medium="image" fileSize="469661">
        <media:title type="plain">Ayele Dilion Mashiah, CEO, Remedy</media:title>
        <media:description type="plain">Ayelet Dilion Mashiah, CEO, Remedy Cell Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>Tortugas launches with $106M for neurology, neuropsychiatric drugs</title>
      <description>
        <![CDATA[Tortugas Neuroscience Inc. came out of its shell to announce the raising of $106 million between its seed and series A financing rounds. “We like the symbolism of the sea turtle – long-lived, persistent, very determined,” Tortugas CEO Jeff Jonas said of the company’s name.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730482</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730482-tortugas-launches-with-106m-for-neurology-neuropsychiatric-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Jeff-Jonas-CEO-and-Al-Robichaud-president-head-of-RD-Tortugas-4-21.webp?t=1776806199" type="image/jpeg" medium="image" fileSize="420579">
        <media:title type="plain">Jeff Jonas, CEO and Al Robichaud, president, head of R&amp;D, Tortugas Neuroscience</media:title>
        <media:description type="plain">Tortugas Neuroscience Inc. is led by Jeff Jonas, CEO (left), 
and Al Robichaud, president and head of R&amp;amp;D.
</media:description>
      </media:content>
    </item>
    <item>
      <title>Remedy pushes ‘cell-free’ secretome therapy for IPF into phase I </title>
      <description>
        <![CDATA[“Single drugs targeting single biological pathways are insufficient for complex diseases,” Remedy Cell Ltd. CEO Ayelet Dilion Mashiah told <em>BioWorld</em>. Remedy is taking a secretome-based approach to treat lung disorders, having moved its lead asset, RC-0315, into a first-in-human clinical trial for idiopathic pulmonary fibrosis (IPF) in January. Secretomes refer to the collection of bioactive molecules secreted by cells in the extracellular space, including proteins, enzymes, growth factors and extracellular vesicles such as exosomes.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730310</guid>
      <pubDate>Wed, 15 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730310-remedy-pushes-cell-free-secretome-therapy-for-ipf-into-phase-i</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/Ayele-Dilion-Mashiah-CEO-Remedy-4-15.webp?t=1776282566" type="image/jpeg" medium="image" fileSize="469661">
        <media:title type="plain">Ayele Dilion Mashiah, CEO, Remedy</media:title>
        <media:description type="plain">Ayelet Dilion Mashiah, CEO, Remedy Cell Ltd.</media:description>
      </media:content>
    </item>
    <item>
      <title>New China biotech Syneron chases macrocycle frontier</title>
      <description>
        <![CDATA[Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730420</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730420-new-china-biotech-syneron-chases-macrocycle-frontier</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Multicolor-peptide-illustration.webp?t=1775668991" type="image/jpeg" medium="image" fileSize="534333">
        <media:title type="plain">Multicolor peptide illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>‘Immune reset’ is ambition of Tr1x’s allogenic Tr1 cell therapy</title>
      <description>
        <![CDATA[Tr1x Inc. was founded with a simple but ambitious goal: to change how autoimmune and inflammatory diseases are treated,&nbsp;moving away from chronic treatment and toward durable cures. “We are trying to flip the script on regulatory T cells (Tregs),” Tr1x CEO David de Vries told <em>BioWorld</em>. “The goal is to reset the immune system rather than continuously suppress it, and we believe we have a unique technology to do that.”]]>
      </description>
      <guid>http://www.bioworld.com/articles/730296</guid>
      <pubDate>Tue, 14 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730296-immune-reset-is-ambition-of-tr1xs-allogenic-tr1-cell-therapy</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Cell-therapy-illustration.webp?t=1758833925" type="image/jpeg" medium="image" fileSize="857445">
        <media:title type="plain">Cell therapy illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Realta secures another $40M for its hypoxic ischemic encephalopathy treatment</title>
      <description>
        <![CDATA[Realta Life Sciences Inc. raised an additional $40 million in the final tranche of its series A investment, bringing the total the company has raised to more than $150 million through mission-driven investors and a family-office model.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730228</guid>
      <pubDate>Fri, 10 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730228-realta-secures-another-40m-for-its-hypoxic-ischemic-encephalopathy-treatment</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Pediatric/newborn-baby-infant.webp?t=1720795419" type="image/jpeg" medium="image" fileSize="169571">
        <media:title type="plain">Photo of hands holding a baby </media:title>
      </media:content>
    </item>
    <item>
      <title>Sidewinder’s bispecific ADC approach draws $137M series B</title>
      <description>
        <![CDATA[Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730275</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730275-sidewinders-bispecific-adc-approach-draws-137m-series-b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-digital-dollar-sign.webp?t=1775054521" type="image/jpeg" medium="image" fileSize="639573">
        <media:title type="plain">Blue digital dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>New China biotech Syneron chases macrocycle frontier</title>
      <description>
        <![CDATA[Syneron Bio is emerging as one of the most heavily backed new entrants in the macrocyclic peptide space, raising more than $250 million in venture funding and securing a multibillion-dollar deal with Astrazeneca plc as it builds a platform spanning several of the most competitive frontiers in drug development.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730152</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730152-new-china-biotech-syneron-chases-macrocycle-frontier</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Multicolor-peptide-illustration.webp?t=1775668991" type="image/jpeg" medium="image" fileSize="534333">
        <media:title type="plain">Multicolor peptide illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Sidewinder’s bispecific ADC approach draws $137M series B</title>
      <description>
        <![CDATA[Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730148</guid>
      <pubDate>Wed, 08 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730148-sidewinders-bispecific-adc-approach-draws-137m-series-b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-digital-dollar-sign.webp?t=1775054521" type="image/jpeg" medium="image" fileSize="639573">
        <media:title type="plain">Blue digital dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Sononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeutics</title>
      <description>
        <![CDATA[Newco Sononeu Inc. has launched to translate more than a decade of basic research in controlling cells with ultrasound into novel, non-invasive therapies for conditions including peripheral and diabetic neuropathy. The underlying technology of sonogenetics provides the ability to manipulate cellular activity via ultrasound-sensitive ion channels that respond to acoustic pressure. These channels may be endogenous, or could be delivered by targeted vectors to specific cell types.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730256</guid>
      <pubDate>Wed, 08 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730256-sononeu-wins-52m-arpa-h-grant-for-ultrasound-activated-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Foot-neuropathy-illustration.webp?t=1775587782" type="image/jpeg" medium="image" fileSize="740144">
        <media:title type="plain">Neuropathy illustrated in legs and feet</media:title>
      </media:content>
    </item>
    <item>
      <title>Sononeu wins $5.2M ARPA-H grant for ultrasound-activated therapeutics</title>
      <description>
        <![CDATA[Newco Sononeu Inc. has launched to translate more than a decade of basic research in controlling cells with ultrasound into novel, non-invasive therapies for conditions including peripheral and diabetic neuropathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730136</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730136-sononeu-wins-52m-arpa-h-grant-for-ultrasound-activated-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Foot-neuropathy-illustration.webp?t=1775587782" type="image/jpeg" medium="image" fileSize="740144">
        <media:title type="plain">Neuropathy illustrated in legs and feet</media:title>
      </media:content>
    </item>
    <item>
      <title>Stipple launches with $100M for novel oncology targets</title>
      <description>
        <![CDATA[Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform. The round was co-led by RA Capital, a16z Bio+Health and Nextech Invest. Existing investors, including Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), Lola Capital Partners, GordonMD Global Investments and others, also participated in the round.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730206</guid>
      <pubDate>Tue, 07 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730206-stipple-launches-with-100m-for-novel-oncology-targets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-in-light-bulb-on-yellow-background.webp?t=1637008317" type="image/png" medium="image" fileSize="77494">
        <media:title type="plain">Dollar sign in light bulb on yellow background</media:title>
      </media:content>
    </item>
    <item>
      <title>Stipple launches with $100M for novel oncology targets</title>
      <description>
        <![CDATA[Stipple Bio Inc. raised $100 million in a series A financing to support progression of the company’s lead drug, STP-100, an antibody-drug conjugate that binds an undisclosed target, and the company’s Pointillist discovery platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730120</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730120-stipple-launches-with-100m-for-novel-oncology-targets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-in-light-bulb-on-yellow-background.webp?t=1637008317" type="image/png" medium="image" fileSize="77494">
        <media:title type="plain">Dollar sign in light bulb on yellow background</media:title>
      </media:content>
    </item>
    <item>
      <title>One-carbon has new approach to starving tumors of nucleotides</title>
      <description>
        <![CDATA[Swedish startup One-carbon Therapeutics AB is going after solid tumors with an approach that looks similar to synthetic lethals to some people, and to chemotherapy to others. But One-carbon CEO Ana Slipicevic said that TH-9619, the company’s first-in-class inhibitor of the enzyme MTHFD1/2, is neither of those things.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730118</guid>
      <pubDate>Mon, 06 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730118-one-carbon-has-new-approach-to-starving-tumors-of-nucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Blue-cancer-cell.webp?t=1753195222" type="image/jpeg" medium="image" fileSize="246736">
        <media:title type="plain">Blue cancer cell</media:title>
      </media:content>
    </item>
    <item>
      <title>Ambrosia slurps up a $100M series B for its oral obesity drug pipeline</title>
      <description>
        <![CDATA[Ambrosia Biosciences Inc., named after the drink of the Greek gods, secured a $100 million series B to advance its preclinical pipeline of oral obesity drugs. The startup formed after Pfizer Inc. shuttered its Boulder, Colo.-based research facility that the pharma gained through its 2019 acquisition of Array Biopharma Inc.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730076</guid>
      <pubDate>Thu, 02 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730076-ambrosia-slurps-up-a-100m-series-b-for-its-oral-obesity-drug-pipeline</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/Pills-bottle-scale-and-measuring-tape.webp?t=1704492123" type="image/jpeg" medium="image" fileSize="266968">
        <media:title type="plain">Pills, bottle, scale and-measuring tape</media:title>
      </media:content>
    </item>
    <item>
      <title>Excalipoint closes $68.7M seed round for cancer T-cell engagers </title>
      <description>
        <![CDATA[Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729898</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729898-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-gray-dollar-sign.webp?t=1773864630" type="image/jpeg" medium="image" fileSize="944348">
        <media:title type="plain">Blue-gray dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Immutrin raises £65M series A to take another run at reversing amyloidosis</title>
      <description>
        <![CDATA[Newco Immutrin Ltd. has raised £65 million (US$86.9 million) in a series A to take its lead antibody program through to clinical proof of concept in transthyretin amyloid cardiomyopathy.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729825</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729825-immutrin-raises-65m-series-a-to-take-another-run-at-reversing-amyloidosis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Heart-scientific-overlay.webp?t=1729781889" type="image/jpeg" medium="image" fileSize="394419">
        <media:title type="plain">Heart scientific overlay</media:title>
      </media:content>
    </item>
    <item>
      <title>Oryon emerges with autologous stem cell therapy for Parkinson’s</title>
      <description>
        <![CDATA[Oryon Cell Therapies, named after the Orion constellation used for navigation at night, emerged from stealth mode to announce a new round of funding and to present data from the phase Ib/IIa study of its neuron replacement therapy in patients with Parkinson’s disease at the 20th International Conference on Alzheimer’s and Parkinson’s Diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729809</guid>
      <pubDate>Mon, 23 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729809-oryon-emerges-with-autologous-stem-cell-therapy-for-parkinsons</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Parkinson's-disease-illustration.webp?t=1643408215" type="image/png" medium="image" fileSize="519828">
        <media:title type="plain">Parkinson's disease illustration showing neurons containing alpha-synuclein</media:title>
      </media:content>
    </item>
    <item>
      <title>Excalipoint closes $68.7M seed round for cancer T-cell engagers </title>
      <description>
        <![CDATA[Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729788</guid>
      <pubDate>Thu, 19 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729788-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-gray-dollar-sign.webp?t=1773864630" type="image/jpeg" medium="image" fileSize="944348">
        <media:title type="plain">Blue-gray dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Excalipoint closes $68.7M seed round for cancer T-cell engagers </title>
      <description>
        <![CDATA[Excalipoint Therapeutics Inc. launched with an oversubscribed $68.7 million seed financing round to advance a portfolio of T-cell engagers for solid tumors, marking one of the largest early stage financings in China biotech history.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729560</guid>
      <pubDate>Wed, 18 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729560-excalipoint-closes-687m-seed-round-for-cancer-t-cell-engagers</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Blue-gray-dollar-sign.webp?t=1773864630" type="image/jpeg" medium="image" fileSize="944348">
        <media:title type="plain">Blue-gray dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Enodia jumps ahead in Sec61 targeting, adds Kezar’s program</title>
      <description>
        <![CDATA[Enodia Therapeutics Inc. was spun out of The Institut Pasteur by Argobio Studio based on the work of Caroline Demangel, co-founder of Enodia and head of the immunobiology and therapy unit at The Institut Pasteur. Demangel’s lab discovered the mechanism of action of mycolactone, a natural Sec61 inhibitor that causes Buruli ulcers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729706</guid>
      <pubDate>Tue, 17 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729706-enodia-jumps-ahead-in-sec61-targeting-adds-kezars-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Tinted-Euro-symbol.webp?t=1685996236" type="image/jpeg" medium="image" fileSize="59509">
        <media:title type="plain">Tinted Euro symbol</media:title>
      </media:content>
    </item>
  </channel>
</rss>
